The state of pharmacotherapy for the treatment of alcohol dependence.
about
Nalmefene: a new approach to the treatment of alcohol dependenceNovel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulationTreatment for comorbid borderline personality disorder and alcohol use disorders: a review of the evidence and future recommendationsProteomic approaches and identification of novel therapeutic targets for alcoholismNoribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administrationThe α1-adrenergic receptor antagonist, doxazosin, reduces alcohol drinking in alcohol-preferring (P) Rats.Dual efficacy of delta opioid receptor-selective ligands for ethanol drinking and anxietyTreatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs.Combining the α1 -adrenergic receptor antagonist, prazosin, with the β-adrenergic receptor antagonist, propranolol, reduces alcohol drinking more effectively than either drug alone.Harm reduction with pharmacotherapy for homeless people with alcohol dependence: protocol for a randomized controlled trial.The pharmacotherapy of alcohol dependence: a state of the art review.Treatment of substance abusing patients with comorbid psychiatric disorders.Medications for addiction treatment: an opportunity for prescribing clinicians to facilitate remission from alcohol and opioid use disordersSocial network moderators of naltrexone and behavioral treatment effects on heavy drinking in the COMBINE study.Effects of prazosin, an α1-adrenergic receptor antagonist, on the seeking and intake of alcohol and sucrose in alcohol-preferring (P) rats.Evidence that Melanocortin Receptor Agonist Melanotan-II Synergistically Augments the Ability of Naltrexone to Blunt Binge-Like Ethanol Intake in Male C57BL/6J MiceSituational Strategies for Self-Control.Prazosin + Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in P Rats with a Protracted History of Extensive Voluntary Alcohol Drinking, Dependence, and Multiple Withdrawals.Molecular targets of alcohol action: Translational research for pharmacotherapy development and screening.Adoption of medications in substance abuse treatment: priorities and strategies of single state authoritiesRole of exercise in the treatment of alcohol use disorders.Effects of sazetidine-A, a selective alpha4beta2 nicotinic acetylcholine receptor desensitizing agent on alcohol and nicotine self-administration in selectively bred alcohol-preferring (P) rats.Medications for substance use disorders.Involvement of delta opioid receptors in alcohol withdrawal-induced mechanical allodynia in male C57BL/6 mice.Daily relations among affect, urge, targeted naltrexone, and alcohol use in young adults.Men Who Have Sex With Men in Peru: Acceptability of Medication-Assisted Therapy for Treating Alcohol Use Disorders.Qualitative and quantitative feedback following workshop training in evidence-based practices: A dissemination study.Binge Alcohol Exposure Transiently Changes the Endocannabinoid System: A Potential Target to Prevent Alcohol-Induced Neurodegeneration.Mining the nucleus accumbens proteome for novel targets of alcohol self-administration in male C57BL/6J mice.Glyoxalase 1 (GLO1) Inhibition or Genetic Overexpression Does Not Alter Ethanol's Locomotor Effects: Implications for GLO1 as a Therapeutic Target in Alcohol Use Disorders.Systemic and Intra-Habenular Activation of the Orphan G Protein-Coupled Receptor GPR139 Decreases Compulsive-Like Alcohol Drinking and Hyperalgesia in Alcohol-Dependent Rats.
P2860
Q24564708-92FE0E05-3F6F-425A-BBEE-9DE909517E68Q26853630-59274D3A-BA75-4EDF-A870-D7681B3B384EQ27002357-8FC0CF8A-7F63-4610-9B5E-AB35C9F8A40BQ27023085-0A91216D-A27B-4352-BCCD-453CD16369D8Q28297349-C9EA20EC-E935-4B4C-8194-537636643F69Q30443459-DA786FA1-03CF-4C0E-8A65-A337FD3BCA61Q30497060-A52F4F16-2C1F-4FA6-8EAE-A13E395BF607Q30751889-F1A280BB-5F08-431F-AC5E-540062361EBBQ33719351-8F5AFEA8-6516-45EC-8141-A665C4693CD8Q33923259-CD664C90-215D-48D6-81E9-9048E57CFF02Q34543952-1BD630E9-CA11-468E-8CA6-6AD0511FFE32Q35387756-43BE056E-5987-4931-B337-32B88E965A40Q35527075-7132E088-5536-49D0-8122-CC425E1C3836Q35565599-22DF227B-9ED6-450C-8A16-AFA0A855A521Q35670393-9197E734-A5DF-4C32-8CA3-5C0C197D8BA4Q35889376-936DCFA5-307D-448A-A55A-A7589CA68366Q35906067-CF56DB53-8747-4455-A1A5-952BACA1E888Q36021630-88EBA1BE-6D15-42B9-AA77-2AC9ACE35496Q36581622-374813C4-BCB5-477F-B1E1-563C9969BEA9Q36806539-63E1A14B-2758-4234-98D5-506809239E76Q36824477-5340FB81-4B9D-4DD6-B651-114E238EC48EQ36963775-E1BE5AE2-40A3-45F8-956E-2404BD620A81Q38111473-BB97246B-D81A-4E16-99BF-BE569C56A316Q39168054-FE998A5F-C86E-44F0-9AA7-D3220BD068B7Q39333954-F7E7F186-F077-4942-9D75-FFFBC41C9646Q41412402-D04C9D3B-AEE1-4F8C-AC85-696760D78C0FQ46856666-82407CB7-9F45-40A0-944B-E8438349D091Q47944859-B8E424B4-8FD6-42BD-95CE-1E23B5D7523BQ51765947-9FF0888B-A95D-421D-B19E-AC5F2BE83E04Q53435599-11CED6AD-8099-4600-9ACF-375935508216Q55494290-E4B6C9C2-9920-4A64-9ABD-9F38E0DB81C4
P2860
The state of pharmacotherapy for the treatment of alcohol dependence.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The state of pharmacotherapy for the treatment of alcohol dependence.
@en
The state of pharmacotherapy for the treatment of alcohol dependence.
@nl
type
label
The state of pharmacotherapy for the treatment of alcohol dependence.
@en
The state of pharmacotherapy for the treatment of alcohol dependence.
@nl
prefLabel
The state of pharmacotherapy for the treatment of alcohol dependence.
@en
The state of pharmacotherapy for the treatment of alcohol dependence.
@nl
P1476
The state of pharmacotherapy for the treatment of alcohol dependence.
@en
P2093
James C Garbutt
P304
S15-23; quiz S24-5
P577
2009-01-01T00:00:00Z